DexCom, Inc. (DXCM) on Decifer

Decifer ranks DXCM number 66 of 277 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 17% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 16% a year, profits grew 47% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• It trades about 18% above similar companies, and its growth does not yet back up that price.
• Strong returns around 17% and profits up 47% with steady high margins make this a strong business, held back by a price about 18% above peers and no worldview role.

The current read

The evidence on DXCM points in two directions at once: a live market force supports this name through its theme connection, while options activity is unusually heavy with positioning leaning toward downside. Until one side gives way, treat the picture as unresolved rather than a clean story.

Themes

• GLP-1 & Metabolic Health: DexCom makes continuous glucose monitors (CGMs). GLP-1 adoption improves metabolic management but may reduce insulin-dependent CGM use over time. Mixed exposure — monitor for direction.

Read the full DXCM research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.